Unfortunately, somatic mutations and predicted major histocompatibility complex (MHC) class I and class II neoantigens were significantly lower in EGFR-mutant NSCLC than in EGFR wild-type tumors (P < 0.01) (74), which inhibited anticancer responses and promoted immune evasion. This evidence concerns the gene EGFR and non-small cell lung carcinoma.